A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

NCT01610388 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Bacterial

Interventions

DRUG: 500mg IV GSK1322322/placebo
DRUG: 1000mg oral GSK1322322/placebo
DRUG: 1000mg IV GSK1322322/placebo
DRUG: 1500mg oral GSK1322322/placebo dose
DRUG: 1500mg IV GSK1322322/placebo
DRUG: 2000mg IV GSK1322322J/placebo
DRUG: 3000mg IV GSK1322322J/placebo
DRUG: 1000mg IV GSK1322322J/placebo

Sponsor

GlaxoSmithKline